Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
China's New Home Prices Continue to Fall in March Despite Signs of Recovery in Major Cities 
Want to cut your energy bills? Here’s how five experts are doing it 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Chile's Kast Unveils 40-Point Economic Reform Package to Boost Growth 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Why the future of marijuana legalization remains hazy despite high public support 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
